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Galanin and its receptors, GALR1 and GALR2, are known tumor suppressors and
potential therapeutic targets in head and neck squamous cell carcinoma (HNSCC).
Previously, we demonstrated that, in GALR1-expressing HNSCC cells, the addition
of galanin suppressed tumor proliferation via upregulation of ERK1 ⁄ 2 and cyclin-
dependent kinase inhibitors, whereas, in GALR2-expressing cells, the addition of
galanin not only suppressed proliferation, but also induced apoptosis. In this
study, we first transduced HEp-2 and KB cell lines using a recombinant adeno-
associated virus (rAAV)-green fluorescent protein (GFP) vector and confirmed a
high GFP expression rate (>90%) in both cell lines at the standard vector dose.
Next, we demonstrated that GALR2 expression in the presence of galanin
suppressed cell viability to 40–60% after 72 h in both cell lines. Additionally, the
annexin V-positive rate and sub-G0 ⁄G1 phase population were significantly
elevated in HEp-2 cells (mock vs GALR2: 12.3 vs 25.0% (P < 0.01) and 9.1 vs 32.0%
(P < 0.05), respectively) after 48 h. These changes were also observed in KB cells,
although to a lesser extent. Furthermore, in HEp-2 cells, GALR2-mediated apopto-
sis was caspase-independent, involving downregulation of ERK1 ⁄ 2, followed by
induction of the pro-apoptotic Bcl-2 protein, Bim. These results illustrate that
transient GALR2 expression in the presence of galanin induces apoptosis via
diverse pathways and serves as a platform for suicide gene therapy against
HNSCC.
H ead and neck squamous cell carcinoma (HNSCC) isdiagnosed in more than 500 000 patients worldwide each
year, accounting for 5% of all malignancies.(1,2) Despite multi-
disciplinary therapy, the prognosis of patients with advanced
HNSCC has remained poor over several decades.(3) Thus, the
invention of new therapeutic approaches against HNSCC, such
as gene therapy and molecular targeted therapies has received
much attention.(4–7) However, these novel treatments remain
inadequate, because various signal transduction systems are
defective in typical HNSCC, and little therapeutic effect is
achieved by therapies targeting single mechanisms. Thus, there
is a need to develop an effective drug delivery system and a
novel molecular targeted therapy with multiple therapeutic
targets.
In general, tyrosine kinase receptors and cytokine receptors,
and their signaling pathways are important in carcinogene-
sis(5,8) and they have been analyzed as molecular targets
and prognostic factors in HNSCC. However, the roles of
G-protein–coupled receptors (GPCRs), which are important
signaling molecules, are not fully understood. GPCRs control
various signaling pathways in all tissues of the body, and
approximately 30% of all current pharmaceuticals exert their
therapeutic effects by interacting with GPCRs. Therefore, the
field of GPCRs holds promise for further drug discovery and
therapeutic development.(9)
Previously, we investigated the function and signal transduc-
tion of galanin receptors, which are representative GPCRs in
HNSCC.(10,11) Galanin is a 30-amino acid peptide, which has
three specific receptors (GALR1–3). Galanin and its receptors
are mainly expressed in the central and peripheral nervous sys-
tems and function in neurotransmission.(12–14) Recently, gala-
nin has been shown to regulate cell proliferation and survival
in many tumors.(15–17) With the development of functional
analysis methods for each receptor, it became clear that
GALR1 and GALR2 are likely to act as tumor suppressors.
Our previous study showed that activation of the GALR1
signaling pathway suppressed tumor cell proliferation via
phosphorylation of ERK1 ⁄2, and involves upregulation of the
cyclin-dependent kinase inhibitors in HNSCC.(10,18) Other
studies showed that GALR1 inhibits proliferation by inactivat-
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ing the mitogen-activated protein kinase (MAPK) pathway in
oral carcinoma.(19) Moreover, activation of the GALR2 signal-
ing pathway suppresses tumor cell growth through induction of
apoptosis in some tumors, including HNSCC.(11,20,21) The
cytotoxic effects of the GALR2 signaling pathway are partially
mediated by dephosphorylation of Akt and the Bcl-2 protein,
Bad, in PC12 cells, a pheochromocytoma cell line.(21)
However, further analysis is required with respect to prog-
nostic factors in HNSCC, applications of molecular targeted
therapy, and clinical applications of gene therapy. The adeno-
associated (AAV) vector is a promising system in gene
therapy, holding various benefits, such as a lack of pathogenic-
ity, low immunogenicity, long-term transgene expression, and
broad tissue-specificity.(22,23) To date, AAV vectors have been
used in clinical trials for the treatment of various diseases,
such as Parkinson’s disease, hemophilia B, and inherited reti-
nal disorders.(24–27) Additionally, it is thought to be applicable
to suicide-gene therapy against various cancers, including
HNSCC.(28–30) rAAV-galanin is currently clinically applied in
the suppression of limbic seizure activity,(31) and this vector is
suitable for use in the galanin–GALR system. Given this back-
ground, we set out to evaluate the effects of GALR expression
on apoptosis and analyzed the associated mechanism of action
using HNSCC cells.
Fig. 1. Transduction efficiency using recombinant adeno-associated virus (rAAV)-enhanced green fluorescent protein (EGFP) in head and neck
squamous cell carcinoma (HNSCC) cell lines. HEp-2 and KB cells were transduced by AAV-EGFP at various vector doses. Upper: GFP-positive cell
rate under vector dose-dependent and time-course conditions in each cell line are indicated. Lower: Raw data expressing GFP intensity as a mea-
sure of gene expression.
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Material and Methods
Cell culture and reagents. Human laryngeal carcinoma cell
line HEp-2 and human oral carcinoma cell line KB were pur-
chased from American Type Culture Collection (Manassas,
VA, USA). Cells were cultured in aMEM (Gibco, Grand
Island, NY, USA) supplemented with 10% heat-inactivated
fetal bovine serum, 100 U ⁄mL penicillin, and 100 lg ⁄mL
streptomycin. Human galanin was obtained from ANASPEC
(San Jose, CA, USA), PD98059 and staurosporine from Wako
(Osaka, Japan), and z-VAD-fmk from Promega (Madison, WI,
USA). Although KB cells were originally thought to be
derived from an epidermal carcinoma of the mouth, HeLa cell
contamination was found thereafter through isoenzyme and
other analyses (http://www.atcc.org/Products/All/CCL-17.aspx).
Therefore, KB cells may not be a pure HNSCC cell line. How-
ever, we used both cell lines to understand the universal func-
tion of GALR2, rather than its cell-specific function.
Plasmid and rAAV vector production. The GALR1HA-Ires-
GFP and GALR2HA-Ires-GFP fragments were obtained from
our previous experiments.(10) The sequences were subcloned
into the pAAV-MCS vector (Agilent technologies, Palo Alto,
CA, USA).
To produce recombinant AAV vectors, we used an AAV
helper-free system (Agilent technologies). Each pAAV vec-
tor, pAAV-RC, and the pHelper plasmid were cotransfected
into subconfluent HEK293 cells by the calcium phosphate
precipitation method or by polyethylenimine. After 72-h
incubation, cells were harvested and lysed using three
freeze-thaw cycles. The crude viral lysate was purified by
two rounds of CsCl density-gradient ultracentrifugation. The
titer of rAAV vectors was subsequently determined by quan-
titative PCR analysis.
Quantitative RT-PCR. Total RNA was isolated using an
RNeasy mini kit (Qiagen, Valencia, CA, USA). Reverse tran-
scription was performed using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s protocol. cDNA was amplified
using TaqMan Expression Assays (Applied Biosystems):
GalR1 (Hs00175668 m1), GalR2 (Hs00605839 m1), and GAP-
DH (Hs99999905 m1). The PCR conditions were as follows:
50°C for 2 min, 95°C for 10 min, and 40 cycles each consist-
ing of 95°C for 15 s and 60°C for 1 min. The expression lev-
els of the target genes were analyzed using the comparative Ct
method, and GAPDH was used as a control gene.
Immunoblotting. Cells were lysed in a buffer containing
62.5 mM Tris-HCl (pH6.8), 2% SDS, 10% glycerol, 6% mer-
captoethanol, and 0.01% bromophenol blue. To detect GALRs
expression, cell lysates were treated with N-Glycosidase F
(New England BioLabs, Beverley, MA, USA) without boiling,
as described previously.(10,11) Mitochondrial and cytosolic frac-
tions were obtained using Mitochondrial Isolation Kit (Ther-
moFisher Scientific, Logan, UT, USA).
Samples were gel electrophoresed and transferred to polyv-
inylidene difluoride membranes, which were probed with
specific antibodies. Mouse monoclonal antibodies to hemag-
glutinin (HA)-tag, phospho-Bad (Ser112), and b-actin, rabbit
monoclonal antibodies to p44 ⁄42 MAPK (Erk1 ⁄2), phospho-
p44 ⁄42 (Thr202 ⁄Tyr204), Akt, phospho-Akt, caspase-3,
cleaved caspase-3, Bax, Bcl-2, Bcl-xL, Mcl-1, Bim, Bad,
survivin, antibodies to Cox IV and XIAP, polyclonal anti-
bodies to AIF, Endonuclease G, Bit1, HtrA2 and cytochrome
c were purchased from Cell Signaling Technology (Beverly,
MA, USA). Bands were visualized using an Enhanced
Chemiluminescence Kit (GE Healthcare, Buckinghamshire,
UK) and an ImageQuant LAS 4000 (Fujifilm, Tokyo,
Japan).
Immunocytochemistry. Cells were seeded onto coverslips and
incubated overnight, and transduced with each recombinant
AAV vector. After 48 h of incubation, cells were fixed, and
stained with mouse monoclonal anti-HA-tag antibody (Cell
Signaling). Subsequently, cells were stained with Alexa Fluor
555-labeled goat anti-mouse IgG (Cell Signaling) and the
nuclei counterstained with DAPI. Furthermore, to determine
the transport potential of HA-tagged GALRs proteins to the
cytoplasmic membrane, HEp-2 cells stably expressing these
proteins were established by transfecting the AAV plasmid
into HEp-2 cells using Lipofectamine (Invitrogen, Carlsbad,
CA, USA). Green fluorescent protein-positive cells were
selected by flow cytometry using a FACS Vantage SE at
4 weeks after transfection (BD Biosciences, San Diego, CA,
USA). Exogenous GALR1 or GALR2 were localized using a
BIOREVO BZ-9000 microscope (Keyence, Osaka, Japan) and
an Olympus FV-500 Confocal Microscope (Olympus Corpora-
tion, Tokyo, Japan).
Cell viability assay. The effect of activation of the GALR
signaling pathways on cell viability was examined using
WST-1 (Roche Diagnostics, East Sussex, UK). Cells were
seeded in a 96-well microculture plate, incubated overnight,
and then cultured in serum-free media (SFM) containing
0.1% bovine serum albumin for 2 h. Subsequently, cells
were exposed to the individual rAAV vectors and galanin
for 24–72 h. WST-1 reagent was added for the last 1–2 h of
the incubation, and the absorbance at 450 nm was measured
(a)
(b)
Fig. 2. Expression of GALR1 and GALR2 using individual recombinant
AAV vectors in head and neck squamous cell carcinoma (HNSCC) cells.
(a) Quantitative RT-PCR was performed to measure GALR1 and GALR2
expression in wild type (Wt) or HNSCC cells transduced by each of the
rAAV vectors. (b) Western blot results showing exogenous GALR1 and
GALR2 expression in Wt or HNSCC cells transduced by each of the
rAAV vectors, as detected by an HA-antibody.
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using a Spectra Max 190 microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
Apoptosis and cell cycle analysis. Apoptotic cells were
detected by staining with phycoerythrin (PE)-conjugated ann-
exin V protein (BD Bioscience, San Jose, CA, USA) and flow
cytometry. Cell cycle analysis was performed with the CycleT-
EST PLUS DNA Reagent Kit (BD Biosciences) and flow
cytometry. Apoptosis-induced DNA fragmentation was mea-
sured for the sub-G0 ⁄G1 cell cycle phase populations.
Statistical analysis. Statistical analysis was performed using
Student’s t-test and Kruskal–Wallis test.
Results
Transduction efficiency of HNSCC cell lines using rAAV-EGFP.
To determine transduction efficiency in HNSCC cell lines
using rAAV vectors, HEp-2 and KB cells were infected with a
rAAV-EGFP vector at various vector doses. After incubation
for 24–72 h, GFP-positive cells were counted by flow cytome-
try. We confirmed a high GFP expression (>90%) in both
HNSCC cell lines transduced by vector doses above 1 9 105
vector genomes (vg) ⁄ cell for 48 h (Fig. 1). Consequently, a
titer of 1 9 105 vg ⁄ cell was used as standard vector dose.
GALR gene expression after transduction of rAAV-GALR vec-
tors. We determined both the endogenous and exogenous
mRNA expression levels of each GALR gene in HEp-2 and
KB cells transduced by rAAV-GALR1 or rAAV-GALR2 by
quantitative RT-PCR. After 48 h of transduction, elevated
mRNA expression levels of exogenous GALR1 and GALR2
were observed in both cell lines (Fig. 2a).
The expression levels of exogenous GALR1 and GALR2
proteins were also assessed by western blot analysis and
immunocytochemistry, using a mouse monoclonal anti-HA tag
antibody, and confirmed robust expression of GALR1 and
GALR2 proteins (Figs 2b,3). Immunofluorescence revealed
that GFP-positive cells showed exogenous expression of GAL-
Rs, which was localized to both the cytoplasm and plasma
membrane in cells transiently transduced with AAV vectors
(Fig. 3a). However, in stable GALRs-expressing HEp-2 cells,
exogenous GALRs located only to the plasma membrane
(Fig. 3b). These results suggested that transient-transduction
impelled movement of a large quantity of these proteins to the
cytoplasm, although these proteins themselves have the poten-
tial to be transported to the plasma membrane, as expected for
a G protein-coupled receptor.
Co-administration of rAAV-GALR2 and galanin inhibits cell pro-
liferation and induces apoptosis. We examined the ability of
each GALR signaling pathway to inhibit HNSCC growth. Cul-
ture of cells in the presence of both rAAV-GALR2 and vary-
ing doses of galanin in SFM for 24–72 h resulted in cell
growth suppression in a time- and dose-dependent manner in
both HNSCC lines, as assessed by WST-1 assay. After 72 h of
stimulation, the cell growth rate was significantly decreased to
40% in HEp-2 and 60% in KB cells (Fig. 4a). In contrast,
(a) (b)
Fig. 3. (a) Exogenous GALR1 and GALR2 localization in head and neck squamous cell carcinoma (HNSCC) cells transiently transduced with each
of the recombinant adeno-associated virus (rAAV) vectors. (b) Exogenous GALR1 and GALR2 localization in HEp-2 cells stably transfected with
each of the AAV plasmids. Images show cells stained with the anti-HA antibody (left-most), green fluorescent protein (GFP) (second from the
left), DAPI (4′6′-diamidino-2-phenylindole dihydrochloride) (second from the right), and merged images (right-most).
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(a)
(b)
(c)
Fig. 4. Co-administration of galanin and recombi-
nant adeno-associated virus (rAAV)-GALR2 during
cell culture inhibited cell proliferation and induced
cell death in head and neck squamous cell
carcinoma (HNSCC) cells. (a) Inhibitory effects of
galanin on growth of HNSCC cells transduced with
the respective rAAV vectors. (b) Flow cytometric
analysis of cell apoptosis using the annexin V.
(c) Cell cycle analysis by flow cytometry. *P < 0.05;
**P < 0.01.
© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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co-administration of rAAV-GALR1 and galanin did not affect
cell proliferation in either cell line (Fig. 4a).
The ability of GALR signaling to induce apoptosis was
assessed by measuring annexin V staining in both cell lines.
Co-treatment of cells with rAAV-GALR2 and galanin (1 lM)
for 48 h significantly induced apoptosis in 25% of HEp-2 cells,
and less markedly induced apoptosis in 16% of KB cells
(Fig. 4b).
Furthermore, changes in the cell cycle distribution after acti-
vation of either GALR pathway were evaluated by flow
cytometry. Co-administration of rAAV-GALR2 vector and gal-
anin (1 lM) for 48 h significantly increased the sub-G0 ⁄G1
phase population, to 32% in HEp-2, and to 16.6% in KB cells
(Fig. 4c), suggesting that DNA fragmentation was induced by
activation of the GALR2 signaling pathway, along with apop-
tosis. No other effects on cell cycle distribution were observed
(Fig. 4c). Additionally, GALR1 activation had no effects on
induction of apoptosis or cell cycle distribution (Fig. 4b,c).
Stimulation of GALR2 signaling downregulates ERK1 ⁄ 2, and
upregulates Bim. As the GALR2-mediated cytotoxic effects
were mainly due to apoptosis induction, we examined whether
stimulation of the GALR2 signaling pathway affected the
phosphorylation states of ERK1 ⁄2 and Akt by immunoblotting.
Sustained dephosphorylation of ERK1 ⁄2 was induced by stim-
ulation of GALR2 signaling in both HNSCC cell lines
(Fig. 5a), but no effect on Akt phosphorylation was observed
(Fig. 5b).
Moreover, we examined the influence of the pathway on key
apoptosis regulators, viz., the Bcl-2 protein and inhibitor of
apoptosis protein (IAP) families. The proapoptotic “BH-3–only”
Bcl-2 protein Bim was upregulated by activation of GALR2
signaling in HEp-2, but not in KB cells (Fig. 5a,c). No other
apoptosis-related proteins investigated were affected by
GALR2 activation in either cell line (Fig. 5c). Additionally,
activation of GALR1 signaling did not affect the phosphoryla-
tion state of ERK or the other apoptotic regulators (Fig. 5c).
PD98059 inhibits cell proliferation and induces apoptosis via
inactivation of the MEK ⁄ ERK pathway in HNSCC cells. To deter-
mine whether dephosphorylation of ERK1 ⁄2 results in cell
growth inhibition and apoptosis induction in HNSCC cells, we
examined the reproducibility of GALR2-mediated cytotoxicity
using a specific ERK (MEK1) inhibitor, PD98059. As
expected, dephosphorylation of ERK1 ⁄ 2 was induced by treat-
ment of both HNSCC cell lines with PD98059 at 20–100 lM
for 48 h (Fig. 6a). When cells were cultured in SFM in the
presence of PD98059 for 48 h, dose-dependent cell growth
suppression (Fig. 6b) and significant apoptosis induction
(Fig. 6c) were observed; these effects were more marked in
HEp-2 cells. In addition, dose-dependent upregulation of Bim
was observed in HEp-2, but not in KB cells, after incubation
with PD98059 for 48 h (Fig. 6a). Thus, the GALR2-mediated
cytotoxic effects involved at least downregulation of ERK1 ⁄2,
while Bim may play a role in modulation of GALR2-mediated
apoptotic sensitivity. However, despite apoptosis induction in
KB cells, Bim activation was not observed, suggesting the
existence of multiple signaling pathways for apoptosis induc-
tion.
GALR2-mediated apoptosis is mainly induced via a caspase-
independent pathway. We further investigated the role of the
caspase signaling pathway in GALR2-mediated apoptosis by
(a) (c)
(b)
Fig. 5. Immunoblotting analysis of the phosphorylation of ERK1 ⁄ 2 and Akt and regulation of key apoptosis regulators by co-administration of
recombinant adeno-associated virus (rAAV)-GALR2 vector and galanin. (a) Effect of galanin on ERK1 ⁄ 2 activation and Bim expression in rAAV-
GALR2 vector-transduced head and neck squamous cell carcinoma (HNSCC) cells. (b) Effect of galanin on Akt activation in GALR-transduced
HNSCC cells. (c) Effects of treatment of cells with galanin and transduction with individual rAAV vectors on the phosphorylation state of ERK1 ⁄ 2
and expression of proteins belonging to the Bcl-2 or IAP families.
Cancer Sci | January 2014 | vol. 105 | no. 1 | 77 © 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Uehara et al.
measuring the cleavage of caspase-3 by immunoblotting. Com-
pared to cells treated with 1 lM staurosporine (STS), minimal
cleavage of caspase-3 was observed after stimulation of
GALR2 signaling pathway in either HNSCC line (Fig. 7a).
Additionally, GALR2-mediated inhibition of cell growth was
not abrogated by pretreatment with the pan-caspase inhibitor
z-VAD-FMK (50 lM) in HEp-2 cells (Fig. 7b).
We further examined whether activation of mitochondrial
apoptosis-related factors were involved in initiating a caspase-
independent pathway. Apoptosis inducers, such as apoptosis
inducing factor (AIF), endonuclease G, HtrA2, and Bit1, are
known to be released from the mitochondria to the cytosol and
the nucleus by caspase-independent apoptotic signals. No
translocation of these proteins in response to GALR2 activa-
tion (Fig. 8) was seen in mitochondrial and cytosolic fractions
from transduced HEp-2 cells cultured with ⁄without galanin
(1 lM) for 48 h.
Discussion
We previously demonstrated the function of the GALR1 and
GALR2 signaling pathways. In HNSCC cell lines, we showed
that stably re-expressed GALR1 suppressed tumor cell prolifer-
ation via ERK1 ⁄2-mediated effects on cyclin-dependent kinase
inhibitors, whereas, in GALR2-transduced HNSCC cells, gala-
nin suppressed cell proliferation and induced apoptosis. Thus,
we deduced that GALR1 and GALR2 function as tumor
suppressors and therefore focused on these proteins as thera-
peutic targets for HNSCC.
Here, we showed that transduction of GALR2 using rAAV
vectors makes HNSCC cells susceptible to galanin-induced
growth inhibition and apoptosis; however, we could not show
anti-tumor effects of rAAV-mediated GALR1 activation in
HNSCC cells. It is unclear why GALR1 and GALR2 have
such different effects. We considered that, because of constitu-
tive phosphorylation of ERK1 ⁄2 even under serum-free culture
conditions in the HNSCC cells used in our experiments, fur-
ther activation of ERK1 ⁄2 by GALR1 activation may not be
critical to cell proliferation and survival in these cells.
Although these mechanisms are thought to be partially
responsible for tumor cell growth inhibition, the apoptosis
induction mechanisms mediated in HNSCC cells by GALR2
activation remain unclear. Our results indicated that downregu-
lation of ERK1 ⁄2 is important as a novel apoptotic mechanism
triggered by GALR2 activation.
Dephosphorylation of ERK1 ⁄2 via stimulation of other
GPCRs has previously been reported. Yamada et al. reported
that angiotensin I type 2 receptor (AT2R) mediated apoptosis
followed by dephosphorylation of MAPK in growth factor-
supported PC12 cells.(32) Others have reported that inhibition of
MAPKs via AT2R was mediated by stimulation of serine ⁄ thre-
onine phosphatase 2A (PP2A).(33) It has been reported that
phosphotyrosine phosphatase DEP-1 ⁄PTPg-dependent dephos-
phorylation of ERK1 ⁄2 is required for inhibition of basic
(a)
(b) (c)
Fig. 6. Effect of the MEK inhibitor PD98059 on head and neck squamous cell carcinoma (HNSCC) cells. (a) Phosphorylation states of ERK1 ⁄ 2
after treatment with PD98059. (b) Effect of PD98059 on proliferation of HNSCC cells. (c) Apoptosis analysis by an Annexin V in HNSCC cells. *P <
0.05, **P < 0.01.
© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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growth factor-dependent cell proliferation mediated by the
stimulating somatostatin receptors in glioma cells.(34,35) There-
fore, we anticipated that some protein phosphatase related to
the dephosphorylation of MAPK cascades may be involved. As
an alternative to protein phosphatase activation, Fushimi et al.
reported that prostaglandin E2 downregulated TNF-a-induced
production of matrix metalloproteinase-1 by inhibiting the Raf-
1 ⁄MEK ⁄ERK cascade through activation of the EP4 prostanoid
receptor.(36) Tumor necrosis factor-a–mediated Raf activation,
involving phosphorylation at Ser338, was suppressed by stimu-
lation of the EP4 receptor; in contrast, phosphorylation of the
inhibitory site on Raf, at Ser259, was stimulated via the EP4
receptor. EP4-mediated Raf inactivation was followed by
dephosphorylation of MEK1 ⁄2 and ERK1 ⁄2. Hence, we exam-
ined whether GALR2 activation affects the phosphorylation
state of MEK1 ⁄ 2, immediately upstream of ERK1 ⁄2. We con-
firmed that at least dephosphorylation of MEK1 ⁄ 2 was induced
by GALR2 activation in HEp-2 cells (data not shown). A com-
prehensive analysis of the influence of the Ras ⁄Raf ⁄MEK ⁄ERK
cascades following activation of the GALR2 signaling pathway
requires further study. In addition to the apoptotic mechanisms
mediated by MAPK inhibition via specific inhibitors,
Eisenmann et al. reported the importance of the MAPK path-
way-downstream effector protein, RSK, and the BH-3-only
proapoptotic protein Bad in melanoma cell survival.(37) More-
over, other groups reported that induction of apoptosis in
melanoma cells following inhibition of MEK is mediated by
the Bcl-2 family members PUMA, Bim, and Mcl-1, as well
as through caspase-independent and AIF-dependent mecha-
nism.(38,39) Therefore, we examined whether these regulators,
including those belonging to the Bcl-2 and the IAP family of
proteins, and caspase-dependent as well as caspase-independent
apoptosis-related proteins, may be associated with the apoptotic
mechanisms triggered by GALR2 activation. We found that
upregulation of Bim is induced by GALR2 activation. Future
studies involving downregulation of Bim expression, for
instance by using siRNA, would verify this relationship further.
Although dephosphorylation of ERK1 ⁄2 by GALR2 activa-
tion was observed in both HNSCC cell lines, significant upreg-
ulation of Bim via GALR2 signaling was only induced in
HEp-2, but not in KB cells. These results imply that there are
both Bim-dependent and Bim-independent unknown pathways
that induce apoptosis, and suggest that the type of pathways
followed downstream of GALR2 depends on the cell line.
We hypothesize that the reason why the therapeutic effect of
AAV-GALR2 in KB cells was less marked than in HEp-2 cells
may be that KB cells do not possess the Bim-dependent path-
way, whereas HEp-2 cells possess both pathways. Wittau
et al.(40) demonstrated that there are multiple signaling path-
ways downstream of GALR2 in small cell lung cancer cells,
resulting from coupling of GALR2 to various G-proteins. Their
results supported our hypothesis that GALR2 has multiple sig-
naling pathways by which apoptosis is induced, and that ERK
inactivation, followed by upregulation of Bim, is associated
with the intensity of apoptosis induction following activation
of GALR2 signaling.
These findings about differences between in HEp-2 and in KB
cells indicate that the pathways involved in GALR2-induced
apoptosis diverge, and the details of these signaling path-
ways remain unclear. For further investigation, we divided
GALR2-induced apoptosis pathways into caspase-dependent
and -independent pathways in order to investigate this phenome-
non further. When investigating the caspase-dependent pathway,
we found that GALR2-inhibition of cell growth was not abro-
gated by the pan-caspase inhibitor z-VAD-FMK. Moreover,
none of the apoptosis inducers of the caspase-independent path-
way that we examined were translocated to the cytosol from the
mitochondria, and activation of members of the IAP and the
(a)
(b)
Fig. 7. Effect of galanin on the caspase signaling pathway in recom-
binant adeno-associated virus (rAAV)-GALR2 vector-transduced head
and neck squamous cell carcinoma (HNSCC) cells. (a) Assessment of
caspase-3 activation by immunoblotting. Staurosporine (STS; 1 lM) for
3 h was used as a positive control for caspase activation. (b) Effect of
a pan-caspase inhibitor (z-VAD-fmk) on GALR2-mediated cytotoxic
effects in HEp-2 cells. As positive control, to indicate the inhibitory
effect of z-VAD-fmk, we used cells exposed to paclitaxel (10 nM) for
48 h.
Fig. 8. Effects of mitochondrial apoptosis-associated proteins in HEp-
2 cell co-administered with each of the recombinant adeno-associated
virus (rAAV)-GALR vectors and galanin. Cox IV and b-actin were used
as protein-loading controls for the mitochondrial and cytosolic
fractions, respectively.
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Bcl-2 protein families, except for Bim, were unchanged by
GALR2 signaling. These results suggested that the apoptotic
pathway induced by GALR2 signaling encompasses other
unknown pathways. Because carcinogenesis of HNSCC is
mainly triggered by extrinsic factors, such as smoking or alco-
hol, which induce various genetic defects, this distinctive feature
makes GALR2 advantageous as a therapeutic gene.
In conclusion, we have shown that GALR2 expression in the
presence of galanin induced apoptosis via diverse pathways;
thus, gene therapy using the GALR2 gene holds promise as a
novel suicide-gene therapy against HNSCC.
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